Phase 2
N=14
Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)
Crohn's Disease
Bottom Line
View on ClinicalTrials.gov: NCT02185183 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Sep 2014
Primary outcome: Primary: Number of Participants With Improved in Disease Activity — 0 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Alequel (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Hadassah Medical Organization
- Primary completion
- Jan 2010
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Improved in Disease Activity |
— | — |
Summary
Oral administration of Alequel, a mixture of proteins derived from the patient's bowel will be tested in patients with inflammatory bowel disease.
Eligibility Criteria
Inclusion Criteria
- Crohn's disease
Exclusion Criteria
- Immune suppression
Data sourced from ClinicalTrials.gov (NCT02185183). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.